Filament Health (FH.NE) shipped their first batch of good manufacturing practices (GMP) certified natural psilocybin into the United States earlier this week, according to a press release. The…
FH.NEO
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been…
Filament Health (FH.NE) to release their unaudited financial results for the second quarter of 2021, a period that ended June 30, 2021. As of June 30, Filament had $7.8…
Filament Health (FH.NE) is developing a pipeline of natural psychedelics products to treat mental health problems like depression and anxiety. August 3, 2021, FH received a patent for the…
In this episode, we take a look at a company that’s on a mission to get safe, natural psychedelics into the hands of everyone who needs them, as soon…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Researching Filament Health (FH.NE) taught me a lot about the psychedelic space and shroom stocks. As someone who is big on eating clean and organic food, it came to…
For the vast majority of the history of human use of psychedelics, they have been seen as something sacred, a gift from God or mother nature herself. Ayahuasca, which…
Filament Health (FH.NE) received the first ever psilocybin (and other associated psychoactive compounds) extraction and standardization patent for a public company by the Canadian Intellectual Property Office today, according…